Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 211 in advanced GI adenocarcinoma
NCT02291614Phase 1Terminated
- Sponsor
- Amgen
- Start
- Nov 2014
- Primary completion
- Nov 2017
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of AMG 211 in gastrointestinal adenocarcinoma (GIAC) (11 arms), sponsored by Amgen. Primary endpoints: Number of Participants With Dose-Limiting Toxicities at 28 days and Number of Participants With Treatment Emergent Adverse Events up to 75.5 days. Started Nov 2014; status: terminated.
02
Drugs
AMG 211
03
Conditions
gastrointestinal adenocarcinoma (GIAC)
Beyond the preview
Go deeper on NCT02291614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02291614.